JP5684333B2 - 放射性ハロゲン標識有機化合物の製造方法 - Google Patents
放射性ハロゲン標識有機化合物の製造方法 Download PDFInfo
- Publication number
- JP5684333B2 JP5684333B2 JP2013133306A JP2013133306A JP5684333B2 JP 5684333 B2 JP5684333 B2 JP 5684333B2 JP 2013133306 A JP2013133306 A JP 2013133306A JP 2013133306 A JP2013133306 A JP 2013133306A JP 5684333 B2 JP5684333 B2 JP 5684333B2
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- amino
- syn
- carboxylic acid
- butoxycarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002285 radioactive effect Effects 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 150000002894 organic compounds Chemical class 0.000 title claims description 7
- 150000002367 halogens Chemical class 0.000 title description 12
- 229910052736 halogen Inorganic materials 0.000 title description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 32
- -1 t-butoxycarbonyl group Chemical group 0.000 claims description 31
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 239000011737 fluorine Substances 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 10
- 239000012217 radiopharmaceutical Substances 0.000 claims description 10
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 10
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- NTEDWGYJNHZKQW-UHFFFAOYSA-N 1-amino-3-fluorocyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC(F)C1 NTEDWGYJNHZKQW-UHFFFAOYSA-N 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- NTEDWGYJNHZKQW-KWCOIAHCSA-N 1-amino-3-fluoranylcyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC([18F])C1 NTEDWGYJNHZKQW-KWCOIAHCSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- NTEDWGYJNHZKQW-DGMDOPGDSA-N fluciclovine ((18)F) Chemical compound OC(=O)[C@]1(N)C[C@H]([18F])C1 NTEDWGYJNHZKQW-DGMDOPGDSA-N 0.000 description 8
- 229940027541 fluciclovine f-18 Drugs 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 229940091173 hydantoin Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- KAOJAYKTZHRBIJ-UHFFFAOYSA-N cyclobutyloxymethylbenzene Chemical compound C=1C=CC=CC=1COC1CCC1 KAOJAYKTZHRBIJ-UHFFFAOYSA-N 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Chemical group 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- HXIXVACPUCDUBU-UHFFFAOYSA-N ethyl 3-fluoro-1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1(C(=O)OCC)CC(F)C1 HXIXVACPUCDUBU-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical class [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical group OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BXNRCFVXPOKXQF-UHFFFAOYSA-N methyl 1-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(trifluoromethylsulfonyloxy)cyclobutane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1(C(=O)OC)CC(OS(=O)(=O)C(F)(F)F)C1 BXNRCFVXPOKXQF-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 125000005543 phthalimide group Chemical group 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- AOYNUTHNTBLRMT-MXWOLSILSA-N 2-Deoxy-2(F-18)fluoro-2-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H]([18F])C=O AOYNUTHNTBLRMT-MXWOLSILSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical group CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- CXSJFWUBXJRTNT-UHFFFAOYSA-N 3-(fluoromethyl)cyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CC(CF)C1 CXSJFWUBXJRTNT-UHFFFAOYSA-N 0.000 description 1
- GPPSQLLIFNWNSB-UHFFFAOYSA-N 3-phenylmethoxycyclobutan-1-one Chemical compound C1C(=O)CC1OCC1=CC=CC=C1 GPPSQLLIFNWNSB-UHFFFAOYSA-N 0.000 description 1
- HWTDMFJYBAURQR-UHFFFAOYSA-N 80-82-0 Chemical group OS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O HWTDMFJYBAURQR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical group OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical class ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- XPHXCNDKWBYJKS-UHFFFAOYSA-N ethyl 1-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(trifluoromethylsulfonyloxy)cyclobutane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1(C(=O)OCC)CC(OS(=O)(=O)C(F)(F)F)C1 XPHXCNDKWBYJKS-UHFFFAOYSA-N 0.000 description 1
- KTVUZBJHOAPDGC-UHFFFAOYSA-N ethyl 3-hydroxycyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(O)C1 KTVUZBJHOAPDGC-UHFFFAOYSA-N 0.000 description 1
- SMVBADCAMQOTOV-UHFFFAOYSA-N ethyl cyclobutanecarboxylate Chemical compound CCOC(=O)C1CCC1 SMVBADCAMQOTOV-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical group N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Description
例えば、PET検査に用いられる放射性医薬品の一つである、[18F]2−フルオロ−2−デオキシ−D−グルコース(以下、「18F−FDG」と称す)は、糖代謝の盛んな部位に集積する性質があるため、糖代謝が盛んな腫瘍を特異的に検出することが可能となる。
ここで、反応液に加える塩基は、反応時に発生する塩酸をトラップできるものであればよく、好ましくはトリエチルアミンを用いることができる。また、用いる量は、塩化チオニルに対し等量以上とする。
塩化チオニルの量は、反応原料であるsyn−1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸に対して等量以上である必要がある。このとき、塩化チオニルの量が少ないと、エチルエステル化反応が十分に進行しないため、好ましくない。また、添加量が多すぎると、より過剰な塩酸が発生し、より多くの塩基を用いる必要が生じるため好ましくない。好ましい態様において、塩化チオニルの量は、syn−1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸に対して、5当量以下とする。
この操作により、syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−ベンジルオキシ−シクロブタン−1−カルボン酸エチルエステルを得ることができる。
また、シクロブタン環の3位の炭素にトリアルキルスタンニル置換基を結合させた化合物を合成する場合は、syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−ヒドロキシ−シクロブタン−1−カルボン酸エチルエステル等のアルコール化合物を酸化させてケトン体又はアルデヒド体とし、ホスホニウムヨードメチレン等のホスホニウム塩を用いたウィティッヒ反応により3位にハロゲン化ビニルを形成した後、水素化トリアルキルスズと反応させることによって、得ることができる。3位の炭素にハロゲンを結合させた化合物については、前記アルコール化合物にハロゲン化水素等を反応させることにより、得ることができる。
anti−[18F]FACBCの合成は、前駆体に放射性フッ素を付加する工程、及び、放射性フッ素を付加した化合物につき脱保護を行う工程の、2段階の工程にて行われる。
例えば、シクロブタン環の3位の炭素にトリアルキルスタンニル置換基を結合させた化合物は、目的に応じた種々の放射性ハロゲンと酸化剤とを加え、反応させることにより、放射性ハロゲン標識化合物を得ることが可能である。また、3位の炭素にハロゲン置換基を結合させた化合物は、求核置換反応又は同位体交換反応を用いて放射性ハロゲン標識することができる。なお、求核置換反応にて放射性ハロゲン標識を行う場合、次のような置換反応をすることができる。例えば、3位の炭素と結合しているハロゲンがヨウ素の場合は、フッ素、塩素、又は臭素に、臭素の場合は、塩素又はフッ素に、塩素の場合はフッ素に置換可能である。
なお、各実施例及び比較例にて実施したガスクロマトグラフィーの分析条件は、下記の条件とした。
カラム : SPB−1(スペルコ社製、30m×0.53mmI.D.、充填剤粒径:3μm)
カラム温度: 40℃(3.3分)→90℃(0.5分)(昇温速度:20℃/分)
注入口温度: 250℃
検出器温度: 220℃
キャリアガス: ヘリウム
スプリット比: 1:10
線速度 : 30cm/秒
syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸エチルエステルの合成
syn−5−(3−ベンジルオキシシクロブタン)ヒダントインは、文献(Jonathan McConathy et al, Applied Radiation and Isotopes, 2003, 58, p.657−666)記載の方法に従って合成した。
炭酸アンモニウム397g(4.13mol相当)および塩化アンモニウム88.4g(1.65mol相当)を水2.86Lに溶解した液に、3−ベンジルオキシシクロブタン1−オン72.8g(0.418mol相当)をエタノール2.86Lに溶解した液を滴下し、室温で30分攪拌した。この液に、シアン化カリウム121.0g(1.86mol相当)を加え、60℃で一晩攪拌した。反応液を濃縮し、得られた黄色い固体を水1.06Lで洗浄して塩を取り除いた。メタノール927mLで共沸した後、シリカゲルカラムクロマトグラフィー(溶離液:ジクロロメタン/メタノール=98/2)で精製し、syn−5−(3−ベンジルオキシシクロブタン)ヒダントイン55.3gを得た。
充分に乾燥させ水分を取り除いたsyn−1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸5.67gを、エタノール200mLに溶解させた。この液に、トリエチルアミン 9.5mL(75mmol相当)を加え、‐78℃にて20分間冷却し、塩化チオニル 4.6mL(62.5mmol相当)を加えた。反応液を、0℃で1時間、室温で1時間それぞれ攪拌した後、95℃の油浴にて、1晩加熱還流した。クロロホルム:メタノール=95:1(目的物のRf値=0.6付近)を展開溶媒として使用したTLC分析(UVとリンモリブデン酸による呈色にて確認)により、反応終了の確認を行った。反応終了確認後、反応液を減圧濃縮してsyn−1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸エチルエステル7.64gを白色結晶として得た。
syn−1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸エチルエステル7.64gを、エタノール:トリエチルアミン=9:1混液250mLに溶解させた。この溶液を氷浴で15分冷却した後、二炭酸ジ-t-ブチル 8.6mL(37.5mmol相当)を加え、室温下1晩攪拌した。ヘキサン:酢酸エチル=1:1(反応目的物のRf値=0.6付近)を展開溶媒として使用したTLC(UV及びモリブデン酸による呈色にて確認)にて、反応終了を確認した。反応終了確認後、反応液を減圧濃縮し、残渣として白色結晶を得た。この残渣に、冷酢酸エチル 150mLと0.5mol/Lの冷塩酸150mLを加え、氷浴下で5分攪拌し、次いで静置分離した。有機層を水150mL×2、飽和炭酸水素ナトリウム水溶液150mL、水150mL×2,飽和食塩水150mL×2の順で抽出・洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮し、黄色油状物を得た。別に、水層を酢酸エチル150mL×2、水150mL×2、飽和食塩水150mLの順で抽出・洗浄し、無水硫酸ナトリウムで乾燥後減圧濃縮することにより、少量の黄色油状物を回収した。一連の操作により、淡黄色油状物8.82gを得た。残渣をシリカゲルカラムクロマトグラフィーにより分離精製(ヘキサン:酢酸エチル=1:1)することにより、白色結晶のsyn−1−(N−(t−ブトキシカルボニル)アミノ)−3−ベンジルオキシ−シクロブタン−1−カルボン酸エチルエステル8.04g(23mmol相当)を得た。
syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−ベンジルオキシ−シクロブタン−1−カルボン酸エチルエステル 8.04g(23mmol相当)にエタノール150mLを加えた後、パラジウム−活性炭素(パラジウム10%)960mgを加え、水素置換、室温下で一晩攪拌した。反応後、セライトを用いた濾過によりパラジウム−活性炭素を濾去し、濾液を減圧濃縮し、残渣として白色結晶5.74gを得た。ヘキサン:酢酸エチル=1:1(反応目的物のRf値=0.2付近)を展開溶媒として使用したTLC分析(UVとニンヒドリンによる呈色にて確認)にて反応追跡を行い、反応終了を確認した。次いで残渣をシリカゲルカラムクロマトグラフィー (ヘキサン:酢酸エチル=1:1,ヘキサン:酢酸エチル=4:1)により分離精製し、白色結晶としてsyn−1−(N−(t−ブトキシカルボニル)アミノ)−3−ヒドロキシ−シクロブタン−1−カルボン酸エチルエステル5.36g(20.7mmol相当)を得た。
syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−ヒドロキシ−シクロブタン−1−カルボン酸エチルエステル2.07g(8mmol)をピリジン26mLに溶解させ、氷浴下20分間攪拌した。無水トリフルオロメタンスルホン酸2.0mL(12mmol相当)を加え、そのまま30分間攪拌した。ヘキサン:ジエチルエーテル=1:1を展開溶媒(反応目的物のRf値=0.6付近)としたTLC分析(ニンヒドリンの呈色にて確認)を用いて反応を追跡し、反応終了を確認した。反応終了を確認後、反応液に水100mLとエーテル100mLを加え、1mol/L塩酸100mL×2、水100mL×2、飽和食塩水100mL×2の順で抽出洗浄した。無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、淡黄色結晶2.78gを得た。この反応混合物をシリカゲルカラムクロマトグラフィーにより分離精製(ヘキサン:ジエチルエーテル=3:1)することにより得られた白色結晶につき、さらにペンタン:ジエチルエーテルを用いて再結晶を行うことにより、syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸エチルエステル1.84g(4.7mmol相当)を得た。
1H−NMR(溶媒:CDCl3、共鳴周波数:500MHz):δ5.41−5.35(m,1H),5.32(b,1H),4.26(q,2H,J=7Hz),3.10−3.02(m,b,4H),1.45(s、9H),1.31(t,3H,J=7.0Hz)
13C−NMR(溶媒:CDCl3、共鳴周波数:125MHz):δ172.60,154.46,118.48,75.88,51.97,40.87,28.29,14.11
syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸メチルエステルを標識前駆体として用いたanti−[18F]FACBCの合成を行い、合成されたanti−[18F]FACBC中の残留溶媒の測定を行った。
syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸メチルエステルは、文献(Jonathan McConathy et al,Applied Radiation and Isotopes,2003,58,p.657−666)記載の方法に従って合成した。
[18F]フッ化物イオン含有H2 18O(放射能量36.63GBq、合成開始時補正値)を、陰イオン交換カラムに通液し、[18F]フッ化物イオンを、吸着捕集した。次いで、該カラムに炭酸カリウム水溶液(133mmol/L/0.3mL)及び40mgのクリプトフィックス222(商品名、メルク社製)をアセトニトリル1.5mLに溶解させた液を通液して[18F]フッ化物イオンを溶出した。
以上の結果より、本発明に係る化合物を標識前駆体として用いることにより、合成したanti−[18F]FACBC中におけるメタノールの残留を防ぎ得る事が確認された。
Claims (3)
- 下記式(1):
放射性フッ素を付加した化合物につき脱保護を行い、[18F]1−アミノ−3−フルオロシクロブタンカルボン酸を放射性医薬品として得る工程と、
を含み、
前記放射性医薬品中にメタノールを実質的に含有しない、放射性ハロゲン標識有機化合物の製造方法。 - R2が、トリフルオロメタンスルホン酸置換基である、請求項1に記載の放射性ハロゲン標識有機化合物の製造方法。
- R3が、t−ブトキシカルボニル基である、請求項1又は2に記載の放射性ハロゲン標識有機化合物の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013133306A JP5684333B2 (ja) | 2005-11-29 | 2013-06-26 | 放射性ハロゲン標識有機化合物の製造方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005343653 | 2005-11-29 | ||
JP2005343653 | 2005-11-29 | ||
JP2013133306A JP5684333B2 (ja) | 2005-11-29 | 2013-06-26 | 放射性ハロゲン標識有機化合物の製造方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547939A Division JP5635225B2 (ja) | 2005-11-29 | 2006-11-28 | 放射性ハロゲン標識有機化合物の前駆体化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013177468A JP2013177468A (ja) | 2013-09-09 |
JP5684333B2 true JP5684333B2 (ja) | 2015-03-11 |
Family
ID=38092157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547939A Active JP5635225B2 (ja) | 2005-11-29 | 2006-11-28 | 放射性ハロゲン標識有機化合物の前駆体化合物 |
JP2013133306A Active JP5684333B2 (ja) | 2005-11-29 | 2013-06-26 | 放射性ハロゲン標識有機化合物の製造方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547939A Active JP5635225B2 (ja) | 2005-11-29 | 2006-11-28 | 放射性ハロゲン標識有機化合物の前駆体化合物 |
Country Status (17)
Country | Link |
---|---|
US (7) | US8758724B2 (ja) |
EP (2) | EP1978015B1 (ja) |
JP (2) | JP5635225B2 (ja) |
KR (3) | KR101608755B1 (ja) |
CN (1) | CN101316812A (ja) |
AU (1) | AU2006319987B2 (ja) |
BR (1) | BRPI0619213B8 (ja) |
CA (1) | CA2629227C (ja) |
ES (1) | ES2663496T3 (ja) |
IL (2) | IL191184A (ja) |
NO (2) | NO341981B1 (ja) |
NZ (1) | NZ568179A (ja) |
PL (1) | PL1978015T3 (ja) |
PT (1) | PT1978015T (ja) |
RU (1) | RU2428415C2 (ja) |
TW (1) | TW200800869A (ja) |
WO (1) | WO2007063824A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3530648B1 (en) | 2006-12-27 | 2023-11-08 | Nihon Medi-Physics Co., Ltd | Process for production of precursor compound for radioactive halogen-labeled organic compound |
US20130217908A1 (en) * | 2010-10-28 | 2013-08-22 | Ge Healthcare Limited | Stabilisation of radiopharmaceutical precursors |
CN103221382B (zh) | 2010-11-29 | 2016-06-01 | 通用电气健康护理有限公司 | 制备pet前体 |
GB201021530D0 (en) * | 2010-12-20 | 2011-02-02 | Ge Healthcare Ltd | Purification of precursor compound by crystallisation |
GB201021523D0 (en) * | 2010-12-20 | 2011-02-02 | Ge Healthcare Ltd | Process simplification for precursor compound |
US9061977B2 (en) | 2010-12-20 | 2015-06-23 | Ge Healthcare Limited | Purification of precursor compound by crystallisation |
DK2683684T3 (en) * | 2011-03-08 | 2018-02-05 | Ge Healthcare Ltd | PREPARATION OF A 1-AMINO-3-HYDROXY-CYCLOBUTANE-1-CARBOXYLIC ACID DERIVATIVE |
ES2546997T3 (es) | 2011-06-14 | 2015-09-30 | Ge Healthcare Limited | Preparación de un precursor para PET |
JP6118318B2 (ja) | 2011-07-21 | 2017-04-19 | ジーイー・ヘルスケア・リミテッド | 前駆体化合物及びその製造方法 |
US11534494B2 (en) | 2011-12-21 | 2022-12-27 | Ge Healthcare Limited | Formulation and method of synthesis |
GB201411569D0 (en) | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Novel formulation and method of synthesis |
US20150231249A1 (en) * | 2011-12-21 | 2015-08-20 | Ge Healthcare Limited | 18f-fluciclovine compositions in citrate buffers |
KR102599293B1 (ko) * | 2015-06-04 | 2023-11-07 | 니혼 메디피직스 가부시키가이샤 | 암의 조기 골 전이의 화상 진단제 |
EP3414176A4 (en) * | 2016-02-12 | 2019-10-16 | Graphic Packaging International, LLC | CARTON WITH HANDLE |
CA3055417A1 (en) * | 2017-03-07 | 2018-09-13 | Nihon Medi-Physics Co., Ltd. | Radioactive fluorine-labeling precursor compound and method for producing radioactive fluorine-labeled compound using same |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360928A (en) * | 1989-10-23 | 1994-11-01 | Research Corporation Technologies, Inc. | Synthesis and use of amino acid fluorides as peptide coupling reagents |
JP3722294B2 (ja) | 1993-02-23 | 2005-11-30 | ワーナー−ランバート・コンパニー | 実質的にアルコールを含有しない医薬組成物の製造方法 |
US5808146A (en) * | 1995-11-09 | 1998-09-15 | Emory University | Amino acid analogs for tumor imaging |
KR100660509B1 (ko) * | 1998-05-15 | 2006-12-22 | 지이 헬쓰케어 리미티드 | 표지된 글루타민 및 라이신 유사체 |
EP1311482B1 (en) | 2000-08-08 | 2007-02-21 | Ortho-McNeil Pharmaceutical, Inc. | Non-imidazole aryloxypiperidines as h3 receptor ligands |
TWI286139B (en) | 2000-10-12 | 2007-09-01 | Chugai Pharmaceutical Co Ltd | Erythromycin derivative having novel crystal structures and processes for their production |
EP1420831A1 (en) | 2001-07-27 | 2004-05-26 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
GB0229695D0 (en) * | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase preparation of 18F-labelled amino acids |
US7390902B2 (en) * | 2003-07-31 | 2008-06-24 | Washington University | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors |
WO2005030677A1 (ja) * | 2003-09-30 | 2005-04-07 | Nihon Medi-Physics Co., Ltd. | 放射性フッ素化合物の製造方法 |
CN101035756A (zh) * | 2004-06-17 | 2007-09-12 | 南卡罗来纳州医科大学研究发展基金会 | 非天然氨基酸 |
EP1889834B1 (en) * | 2005-05-23 | 2011-04-20 | Nihon Medi-Physics Co., Ltd. | Novel organic compound and method for producing radioactive halogen-labeled organic compound using the same |
EP1893244A4 (en) * | 2005-06-23 | 2009-06-24 | Univ Emory | CONTRAST AGENTS |
EP1893246A4 (en) | 2005-06-23 | 2009-05-06 | Univ Emory | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGUE FOR TUMOR IMAGING |
NZ572936A (en) | 2006-05-11 | 2011-01-28 | Nihon Mediphysics Co Ltd | Process for production of [18F]1-amino-3-fluorocyclobutanecarboxylic acid, [18F]FACBC |
CA2672262C (en) | 2006-12-21 | 2016-07-05 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
EP3530648B1 (en) | 2006-12-27 | 2023-11-08 | Nihon Medi-Physics Co., Ltd | Process for production of precursor compound for radioactive halogen-labeled organic compound |
US8343459B2 (en) | 2007-02-13 | 2013-01-01 | Nihon Medi-Physics Co., Ltd. | Method for production of radiation diagnostic imaging agent |
MX2010006901A (es) | 2007-12-19 | 2010-09-30 | Nihon Mediphysics Co Ltd | Proceso para la produccion del compuesto organico marcado con fluor radioactivo. |
-
2006
- 2006-11-28 AU AU2006319987A patent/AU2006319987B2/en active Active
- 2006-11-28 WO PCT/JP2006/323659 patent/WO2007063824A1/ja active Application Filing
- 2006-11-28 US US12/085,679 patent/US8758724B2/en active Active
- 2006-11-28 NZ NZ568179A patent/NZ568179A/en unknown
- 2006-11-28 JP JP2007547939A patent/JP5635225B2/ja active Active
- 2006-11-28 EP EP06833463.0A patent/EP1978015B1/en active Active
- 2006-11-28 RU RU2008126277/04A patent/RU2428415C2/ru active
- 2006-11-28 KR KR1020147023255A patent/KR101608755B1/ko active IP Right Grant
- 2006-11-28 PL PL06833463T patent/PL1978015T3/pl unknown
- 2006-11-28 EP EP18160037.0A patent/EP3354639B1/en active Active
- 2006-11-28 KR KR1020087012348A patent/KR20080071146A/ko active Search and Examination
- 2006-11-28 KR KR1020137022428A patent/KR101643991B1/ko active IP Right Grant
- 2006-11-28 CN CNA2006800448187A patent/CN101316812A/zh active Pending
- 2006-11-28 TW TW095143886A patent/TW200800869A/zh unknown
- 2006-11-28 BR BRPI0619213A patent/BRPI0619213B8/pt active IP Right Grant
- 2006-11-28 CA CA2629227A patent/CA2629227C/en active Active
- 2006-11-28 ES ES06833463.0T patent/ES2663496T3/es active Active
- 2006-11-28 PT PT68334630T patent/PT1978015T/pt unknown
-
2008
- 2008-05-01 IL IL191184A patent/IL191184A/en active IP Right Grant
- 2008-06-24 NO NO20082877A patent/NO341981B1/no active Protection Beyond IP Right Term
-
2013
- 2013-06-26 JP JP2013133306A patent/JP5684333B2/ja active Active
-
2014
- 2014-04-07 US US14/246,594 patent/US9381259B2/en active Active
- 2014-10-07 IL IL235029A patent/IL235029A/en active IP Right Grant
-
2015
- 2015-08-21 US US14/814,185 patent/US9387266B2/en active Active
- 2015-10-01 US US14/872,305 patent/US10010632B2/en active Active
-
2018
- 2018-01-04 NO NO20180010A patent/NO20180010A1/no not_active Application Discontinuation
- 2018-05-11 US US15/977,522 patent/US11083804B2/en active Active
-
2020
- 2020-04-20 US US16/852,910 patent/US10953112B2/en active Active
-
2021
- 2021-06-24 US US17/356,757 patent/US20210386873A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5684333B2 (ja) | 放射性ハロゲン標識有機化合物の製造方法 | |
JP4550141B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
JP4989467B2 (ja) | 新規有機化合物及び該化合物を利用した放射性ハロゲン標識有機化合物の製造方法 | |
JP5732198B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
JP5518337B2 (ja) | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130711 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130711 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140924 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5684333 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |